{"id":15616,"date":"2025-11-28T12:20:42","date_gmt":"2025-11-28T06:50:42","guid":{"rendered":"https:\/\/www.torusdigital.com\/toruscope\/?p=15616"},"modified":"2025-11-28T12:30:01","modified_gmt":"2025-11-28T07:00:01","slug":"sudeep-pharma-ipo-opens-key-details-investors-shouldnt-miss-2","status":"publish","type":"post","link":"https:\/\/www.torusdigital.com\/toruscope\/news\/sudeep-pharma-ipo-opens-key-details-investors-shouldnt-miss-2\/","title":{"rendered":"Sudeep Pharma IPO: Shares Make Strong Debut with Over 23% Listing Premium"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_section el_id=&#8221;blog-inner-layout&#8221;][vc_row overlay_dotted=&#8221;&#8221;][vc_column el_class=&#8221;blog_primary&#8221;][vc_row_inner][vc_column_inner][vc_column_text css=&#8221;&#8221;]<\/p>\n<p><a href=\"https:\/\/www.torusdigital.com\/stocks\/sudeep-pharma-ltd-share-price\">Sudeep Pharma<\/a> delivered a confident debut on the Indian stock exchanges on 28 November 2025, marking a notable entry into the public markets. The company\u2019s shares opened significantly higher than the issue price, reflecting strong investor interest and the enthusiasm observed during the IPO bidding phase.<\/p>\n<p>The stock listed at \u20b9733.95 on the BSE and \u20b9730 on the NSE, compared with the issue price of \u20b9593. This reflects a listing premium of 23.76% on the BSE and 23.10% on the NSE. The robust start mirrors the exceptional response during the IPO, which raised \u20b9895 crore through a mix of fresh issuance and an offer for sale.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Subscription_Highlights\"><\/span><strong>Subscription Highlights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The IPO saw remarkable demand, closing with an overall subscription of 93.71 times.<\/p>\n<ul>\n<li><strong>QIB investors<\/strong> led the response at 213.08 times.<\/li>\n<li><strong>NIIs<\/strong> followed at 116.72 times.<\/li>\n<li><strong>Retail investors<\/strong> subscribed to their portion 15.65 times.<\/li>\n<\/ul>\n<p>This extensive participation reflects broad confidence in the company\u2019s position in the global excipients and speciality nutrition ingredients market.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Business_Overview\"><\/span><strong>Business Overview<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Sudeep Pharma is a major producer of:<\/p>\n<ul>\n<li>Pharmaceutical excipients<\/li>\n<li>Food-grade minerals<\/li>\n<li>Speciality nutrition ingredients<\/li>\n<\/ul>\n<p>The company supplies to over 100 countries and operates six manufacturing facilities with a combined annual capacity of 50,000 MT. Its portfolio includes more than 200 specialised products, spanning calcium, magnesium, potassium, zinc, iron, and sodium ingredients. These solutions are used extensively in pharmaceuticals, nutraceuticals, food processing, and speciality nutrition products.<\/p>\n<p>Sudeep Pharma has built strong in-house R&amp;D capabilities supported by laboratories and pilot plants focused on mineral salts and ingredient innovation. It also maintains long-standing relationships with global pharmaceutical and nutrition brands.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Financial_Performance\"><\/span><strong>Financial Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The company reported steady growth in FY25:<\/p>\n<ul>\n<li><strong>Revenue:<\/strong> \u20b9511.33 crore, up 10% from FY24<\/li>\n<li><strong>Net Profit:<\/strong> \u20b9138.69 crore, slightly higher than the previous year<\/li>\n<li><strong>EBITDA Margin:<\/strong> 39.7%<\/li>\n<li><strong>PAT Margin:<\/strong> 27.6%<\/li>\n<\/ul>\n<p>These numbers highlight consistent profitability and efficient operations within a high-entry-barrier industry.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Use_of_IPO_Proceeds\"><\/span><strong>Use of IPO Proceeds<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>From the fresh issue component, Sudeep Pharma plans to allocate \u20b975.8 crore towards capital expenditure for acquiring machinery at its Nandesari Facility 1 in Gujarat. The remaining funds will be directed towards general corporate purposes.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Industry_Outlook\"><\/span><strong>Industry Outlook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>India\u2019s food and nutritional ingredients market is expanding steadily. The broader ingredients sector, valued at $22 billion in 2024, is projected to grow to $32 billion by 2029, driven by rising health awareness and disposable incomes. The vitamins and minerals segment is expected to see similar momentum, growing from $2.1 billion to $3 billion during the same period.<\/p>\n<p>Sudeep Pharma\u2019s established capabilities, global reach, and technology-driven processes place it in a favourable position to benefit from these long-term trends.<\/p>\n<p><em><strong>People Also Read:<\/strong><\/em><\/p>\n<ul>\n<li class=\"post-title\"><em><a href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/excelsoft-technologies-shares-list-at-12-percent-premium\/\">Excelsoft Technologies IPO: Shares List at a 12.5% Premium on NSE &amp; BSE<\/a><\/em><\/li>\n<li class=\"post-title\"><em><a href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/capillary-technologies-ipo-lists-at-571\/\">Capillary Technologies IPO: Shares List Marginally Lower at \u20b9571.90 on NSE<\/a><\/em><\/li>\n<li class=\"post-title\"><em><a href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/fujiyama-power-systems-ipo-makes-a-weak-debut\/\">Fujiyama Power Systems IPO: Shares Make Weak Market Debut, List at 4% Discount<\/a><\/em><\/li>\n<li class=\"post-title\"><em><a href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/tenneco-clean-air-makes-a-strong-debut\/\">Tenneco Clean Air IPO Listing: Strong Market Debut with 27% Premium<\/a><\/em><\/li>\n<li class=\"post-title\"><em><a href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/emmvee-photovoltaic-ipo-lists-flat\/\">Emmvee Photovoltaic IPO: Shares Make Muted Market Debut, List Flat At \u20b9217<\/a><\/em><\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Sudeep Pharma\u2019s strong listing highlights the confidence investors have in its industry leadership, expansive product portfolio and global reach. With its well-established manufacturing base, consistent financial performance, and ongoing capacity expansion, the company has entered the public markets on a firm footing.<\/p>\n<p>If you are exploring more investment opportunities, check out our dedicated page on <a href=\"https:\/\/www.torusdigital.com\/ipo\/upcoming-ipo\">upcoming IPO<\/a> listings to stay updated on the latest market offerings.<\/p>\n<p>[\/vc_column_text][\/vc_column_inner][vc_column_inner width=&#8221;1\/2&#8243;][vc_column_text css=&#8221;&#8221;][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_id=&#8221;share_rating&#8221;][vc_column_inner width=&#8221;1\/2&#8243;][vc_column_text css=&#8221;&#8221;]<\/p>\n<h6>Rate this article<\/h6>\n<!-- FeedbackWP Plugin --><div  class=\"rmp-widgets-container rmp-wp-plugin rmp-main-container js-rmp-widgets-container js-rmp-widgets-container--15616 \"  data-post-id=\"15616\">    <!-- Rating widget -->  <div class=\"rmp-rating-widget js-rmp-rating-widget\">            <div class=\"rmp-rating-widget__icons\">      <ul class=\"rmp-rating-widget__icons-list js-rmp-rating-icons-list\">                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Terrible!\" data-value=\"1\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star rmp-icon--full-highlight\"><\/i>          <\/li>                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Bad!\" data-value=\"2\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star rmp-icon--full-highlight\"><\/i>          <\/li>                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Okay!\" data-value=\"3\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star rmp-icon--full-highlight\"><\/i>          <\/li>                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Good!\" data-value=\"4\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star rmp-icon--half-highlight js-rmp-replace-half-star\"><\/i>          <\/li>                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Great!\" data-value=\"5\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star \"><\/i>          <\/li>              <\/ul>    <\/div>    <p class=\"rmp-rating-widget__hover-text js-rmp-hover-text\"><\/p>    <button class=\"rmp-rating-widget__submit-btn rmp-btn js-submit-rating-btn\">      Submit Rating    <\/button>    <p class=\"rmp-rating-widget__results js-rmp-results \">       <span class=\"rmp-rating-widget__results__rating js-rmp-avg-rating\">3.7<\/span> \/ 5.  <span class=\"rmp-rating-widget__results__votes js-rmp-vote-count\">6<\/span>    <\/p>    <p class=\"rmp-rating-widget__not-rated js-rmp-not-rated rmp-rating-widget__not-rated--hidden\">          <\/p>    <p class=\"rmp-rating-widget__msg js-rmp-msg\"><\/p>  <\/div>  <!--Structured data -->        <\/div>\n<div id=\"emoji-overlay\" style=\"display: none;\">\n<div id=\"overlay-emoji\"><\/div>\n<div id=\"overlay-description\" class=\"emoji-text\"><\/div>\n<\/div>\n<div id=\"rating-popup\">\n<p><span id=\"popup-close\">\u00d7<\/span><\/p>\n<div class=\"popup_message\">\n<div id=\"popup-emoji\"><\/div>\n<div class=\"popup_innermsg\">\n<h5>Thank You for Rating Our Article!<\/h5>\n<p>Your feedback is incredibly valuable to us, and we&#8217;re thrilled to hear your thoughts.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<p>[\/vc_column_text][\/vc_column_inner][vc_column_inner width=&#8221;1\/2&#8243;][vc_column_text css=&#8221;&#8221;]<\/p>\n<h6>Share this article<\/h6>\n<div class=\"cscra-social square cscra-socials-679c8a1122c00\">\n        <a href=\"\/\/www.facebook.com\/sharer\/sharer.php?u=https%3A%2F%2Fwww.torusdigital.com%2Ftoruscope%2Fnews%2Fsudeep-pharma-ipo-opens-key-details-investors-shouldnt-miss-2%2F&t=Sudeep+Pharma+IPO%3A+Shares+Make+Strong+Debut+with+Over+23%25+Listing+Premium\" class=\"facebook\" data-toggle=\"tooltip\" data-placement=\"top\" title=\"Share On Facebook\" target=\"_blank\"><i class=\"fa fa-facebook\"><\/i><\/a>\n        <a href=\"\/\/twitter.com\/intent\/tweet?text=Sudeep+Pharma+IPO%3A+Shares+Make+Strong+Debut+with+Over+23%25+Listing+Premium&url=https%3A%2F%2Fwww.torusdigital.com%2Ftoruscope%2Fnews%2Fsudeep-pharma-ipo-opens-key-details-investors-shouldnt-miss-2%2F\" class=\"twitter\" data-toggle=\"tooltip\" data-placement=\"top\" title=\"Share On Twitter\" target=\"_blank\"><i class=\"fa-brands fa-x-twitter\"><\/i><\/a>\n        <a href=\"https:\/\/api.whatsapp.com\/send?text=Sudeep+Pharma+IPO%3A+Shares+Make+Strong+Debut+with+Over+23%25+Listing+Premium - https%3A%2F%2Fwww.torusdigital.com%2Ftoruscope%2Fnews%2Fsudeep-pharma-ipo-opens-key-details-investors-shouldnt-miss-2%2F\" class=\"whatsapp\" data-toggle=\"tooltip\" data-placement=\"top\" title=\"Share On WhatsApp\" target=\"_blank\"><i class=\"fa fa-whatsapp\"><\/i><\/a>\n        <a href=\"\/\/www.linkedin.com\/shareArticle?mini=true&url=https%3A%2F%2Fwww.torusdigital.com%2Ftoruscope%2Fnews%2Fsudeep-pharma-ipo-opens-key-details-investors-shouldnt-miss-2%2F&title=Sudeep+Pharma+IPO%3A+Shares+Make+Strong+Debut+with+Over+23%25+Listing+Premium\" class=\"linkedin\" data-toggle=\"tooltip\" data-placement=\"top\" title=\"Share On Linkedin\" target=\"_blank\"><i class=\"fa fa-linkedin\"><\/i><\/a>\n    <\/div>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][\/vc_section]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"[vc_section el_id=&#8221;blog-inner-layout&#8221;][vc_row overlay_dotted=&#8221;&#8221;][vc_column el_class=&#8221;blog_primary&#8221;][vc_row_inner][vc_column_inner][vc_column_text css=&#8221;&#8221;] Sudeep Pharma delivered a confident debut on the Indian stock exchanges on 28 November 2025, marking a notable entry into the public markets. The company\u2019s shares opened significantly higher than the issue price, reflecting strong investor interest and the enthusiasm observed during the IPO bidding phase. The stock listed at","protected":false},"author":1,"featured_media":14110,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_sitemap_exclude":false,"_sitemap_priority":"","_sitemap_frequency":"","footnotes":""},"categories":[5,169],"tags":[],"class_list":["post-15616","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ipo","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Sudeep Pharma IPO Makes Strong Market Debut with 24% Listing Premium<\/title>\n<meta name=\"description\" content=\"Sudeep Pharma lists at a 24% premium over its IPO price, supported by solid subscription levels and its global leadership in excipients and speciality nutrition ingredients. Learn more about the company\u2019s business scale, financial performance, and listing highlights.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/sudeep-pharma-ipo-opens-key-details-investors-shouldnt-miss-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sudeep Pharma IPO Makes Strong Market Debut with 24% Listing Premium\" \/>\n<meta property=\"og:description\" content=\"Sudeep Pharma lists at a 24% premium over its IPO price, supported by solid subscription levels and its global leadership in excipients and speciality nutrition ingredients. Learn more about the company\u2019s business scale, financial performance, and listing highlights.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.torusdigital.com\/toruscope\/news\/sudeep-pharma-ipo-opens-key-details-investors-shouldnt-miss-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-28T06:50:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-28T07:00:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Aditya-Infotech-Ltd-Mainboard-IPO.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1441\" \/>\n\t<meta property=\"og:image:height\" content=\"466\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"torus\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"torus\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sudeep Pharma IPO Makes Strong Market Debut with 24% Listing Premium","description":"Sudeep Pharma lists at a 24% premium over its IPO price, supported by solid subscription levels and its global leadership in excipients and speciality nutrition ingredients. Learn more about the company\u2019s business scale, financial performance, and listing highlights.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.torusdigital.com\/toruscope\/news\/sudeep-pharma-ipo-opens-key-details-investors-shouldnt-miss-2\/","og_locale":"en_US","og_type":"article","og_title":"Sudeep Pharma IPO Makes Strong Market Debut with 24% Listing Premium","og_description":"Sudeep Pharma lists at a 24% premium over its IPO price, supported by solid subscription levels and its global leadership in excipients and speciality nutrition ingredients. Learn more about the company\u2019s business scale, financial performance, and listing highlights.","og_url":"https:\/\/www.torusdigital.com\/toruscope\/news\/sudeep-pharma-ipo-opens-key-details-investors-shouldnt-miss-2\/","og_site_name":"Blog","article_published_time":"2025-11-28T06:50:42+00:00","article_modified_time":"2025-11-28T07:00:01+00:00","og_image":[{"width":1441,"height":466,"url":"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Aditya-Infotech-Ltd-Mainboard-IPO.webp","type":"image\/webp"}],"author":"torus","twitter_card":"summary_large_image","twitter_misc":{"Written by":"torus","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/sudeep-pharma-ipo-opens-key-details-investors-shouldnt-miss-2\/","url":"https:\/\/www.torusdigital.com\/toruscope\/news\/sudeep-pharma-ipo-opens-key-details-investors-shouldnt-miss-2\/","name":"Sudeep Pharma IPO Makes Strong Market Debut with 24% Listing Premium","isPartOf":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/sudeep-pharma-ipo-opens-key-details-investors-shouldnt-miss-2\/#primaryimage"},"image":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/sudeep-pharma-ipo-opens-key-details-investors-shouldnt-miss-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Aditya-Infotech-Ltd-Mainboard-IPO.webp","datePublished":"2025-11-28T06:50:42+00:00","dateModified":"2025-11-28T07:00:01+00:00","author":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/#\/schema\/person\/468d817c6d51cdd85d58071858a47ce5"},"description":"Sudeep Pharma lists at a 24% premium over its IPO price, supported by solid subscription levels and its global leadership in excipients and speciality nutrition ingredients. Learn more about the company\u2019s business scale, financial performance, and listing highlights.","breadcrumb":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/sudeep-pharma-ipo-opens-key-details-investors-shouldnt-miss-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.torusdigital.com\/toruscope\/news\/sudeep-pharma-ipo-opens-key-details-investors-shouldnt-miss-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/sudeep-pharma-ipo-opens-key-details-investors-shouldnt-miss-2\/#primaryimage","url":"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Aditya-Infotech-Ltd-Mainboard-IPO.webp","contentUrl":"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Aditya-Infotech-Ltd-Mainboard-IPO.webp","width":1441,"height":466},{"@type":"BreadcrumbList","@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/sudeep-pharma-ipo-opens-key-details-investors-shouldnt-miss-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Toruscope","item":"https:\/\/www.torusdigital.com\/toruscope\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.torusdigital.com\/toruscope\/.\/news\/"},{"@type":"ListItem","position":3,"name":"Sudeep Pharma IPO: Shares Make Strong Debut with Over 23% Listing Premium"}]},{"@type":"WebSite","@id":"https:\/\/www.torusdigital.com\/toruscope\/#website","url":"https:\/\/www.torusdigital.com\/toruscope\/","name":"Blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.torusdigital.com\/toruscope\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.torusdigital.com\/toruscope\/#\/schema\/person\/468d817c6d51cdd85d58071858a47ce5","name":"torus","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.torusdigital.com\/toruscope\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/09645f2c6ef6bbb3a78db22600040d547bed4438a393e0671d168d69d193bc19?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/09645f2c6ef6bbb3a78db22600040d547bed4438a393e0671d168d69d193bc19?s=96&d=mm&r=g","caption":"torus"},"sameAs":["https:\/\/stage.torusdigital.com\/blogs"],"url":"https:\/\/www.torusdigital.com\/toruscope\/author\/torus\/"}]}},"_links":{"self":[{"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/posts\/15616","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/comments?post=15616"}],"version-history":[{"count":1,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/posts\/15616\/revisions"}],"predecessor-version":[{"id":15617,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/posts\/15616\/revisions\/15617"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/media\/14110"}],"wp:attachment":[{"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/media?parent=15616"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/categories?post=15616"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/tags?post=15616"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}